GlassScriptPhysician profile
Anh Hoang
NPI 1114380581
$2,380.10
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,380.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $499.86 | 2019 | |
| Neurocrine Biosciences, INC. | $256.60 | 2019 | |
| Merck Sharp & Dohme LLC | $210.13 | 2019 | |
| Genentech USA, INC. | $134.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $126.26 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $122.76 | 2019 | |
| Amgen INC. | $122.02 | 2019 | |
| Vifor Pharma, INC. | $119.02 | 2019 | |
| Jazz Pharmaceuticals INC. | $119.02 | 2019 | |
| Tesaro, INC. | $119.02 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $118.14 | 2019 | |
| Gilead Sciences, INC. | $113.35 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $111.86 | 2019 | |
| Abbvie INC. | $109.91 | 2019 | |
| Lilly USA, LLC | $97.45 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anh Hoang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.